STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells
As elite hunters of the immune system, T cells are constantly prowling our bodies for…
Category: STAT+
STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started
The brain remains both the body’s most important organ and its least understood. But a…
STAT+: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to…
STAT+: EU orders Illumina to divest cancer diagnostics firm Grail
LONDON — European regulators on Thursday detailed their demands that Illumina divest the cancer diagnostics…
.jpg)
STAT+: Peter Marks on creating Operation Warp Speed, but for rare diseases
Peter Marks wants drug developers to ask more stupid questions. It’s part of the top…
STAT+: Life sciences deals on track to hit lowest point since 2017
It’s no secret that biotech industry funding has fallen from its Covid highs. But with…
STAT+: Key takeaways from AdvaMed, the world’s largest medical device conference
ANAHEIM, Calif. — Thousands of workers in the medical device industry gathered here this week…
STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer
A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine…
STAT+: Humana CEO Bruce Broussard to step down next year
Bruce Broussard, CEO of health insurance giant Humana, will step down next year after leading…
STAT+: Medicare may plan to negotiate drug prices, but some states are taking their own steps to lower costs
Anticipation may be high that Medicare can wring lower prices out of drugmakers, but a…
STAT+: European regulators consider appeal over Amylyx ALS drug
LONDON — This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially…
STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: ‘Like playing the lottery’: A mixed picture for laid-off life sciences workers in Massachusetts
Gina Calvanese got laid off from Jounce Therapeutics, a struggling Cambridge biotech, in April but…
STAT+: Bernie Sanders bashes nonprofit hospitals over their tax breaks
WASHINGTON — Hospitals get tax breaks that are worth far more than the value of…
STAT+: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital
One of the first items on Laurie Glimcher’s agenda after becoming CEO of the renowned…
STAT+: Sana to lay off nearly a third of staff, de-prioritize a key program
Sana Biotechnology, a startup that just a couple years ago raised over $1 billion off…
STAT+: A fraught question for the children of Alzheimer’s: Is it coming for us?
My sister has a fantasy about our old age: She imagines that the seven siblings…
STAT+: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech…
STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024
Hello, everyone, and nice to see you again. We have returned from an extended weekend…
STAT+: Akero’s treatment for NASH falls short in cirrhosis study
Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for…
STAT+: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential
Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics: A take-under deal feels meh…
STAT+: FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart…
STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect…
STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit
LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined…
STAT+: Venture capital firm General Catalyst wants to buy a health system
Venture firms, convinced they’re jumpstarting the world’s most helpful tech products, have struggled mightily to…
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…
STAT+: Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says
Within the linings of our guts, immune cells patrol like sentries on a castle wall….
STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: How payer-participating trials could help transform clinical research on FDA-approved drugs
Earlier this year, Food and Drug Administration Commissioner Robert M. Califf proposed something radical: that…
STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following…
STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug
SAN DIEGO — Neurocrine Biosciences, a biotech focused on treating rare neurological and endocrine diseases,…
STAT+: Telehealth claims data suggest service duplication, Roche app to evaluate MS symptom
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech…
STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in…
STAT+: 3 questions for the future of Biden’s cancer moonshot
WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few…
STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise
SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions…
STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug…
STAT+: Federal bill would keep addiction medication from triggering a child abuse investigation
When Keri McCallum‘s doctor prescribed her Suboxone, she was told it was the “safest thing…
STAT+: Key Senate panel eyes action on drug shortages
WASHINGTON — One of the top health care committees in the Senate is assembling ideas…
STAT+: Consumer watchdog sues diagnostic firm EpicGenetics, alleging misleading claims about fibromyalgia test
The consumer watchdog group the Center for Science in the Public Interest filed a lawsuit…
STAT+: To prevent amputation in patients with severe vascular disease, a device turns veins into arteries
An innocuous slip while cutting her toenails created a wound on Cynthia Elford’s right foot…
STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases
Several cases of sepsis — three of which ended in patients deaths — were traced…
STAT+: Pharmalittle: FDA finds ‘potential systemic bias’ in Amgen cancer drug trial; drugmakers organize to push back on antitrust reviews
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again
LONDON — It was when she was 12 that doctors first raised the prospect of…
STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
In the latest battle over access to medicines, Colombian authorities have decided to issue a…
STAT+: FDA finds ‘potential systemic bias’ in Amgen’s KRAS drug trial ahead of advisory meeting
A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and…
STAT+: Pharmalittle: Drugmakers agree to negotiate Medicare prices under protest; AstraZeneca settles lawsuits over heartburn drugs
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Lilly bolts another one on, acquiring Point Therapeutics for $1.4 billion
A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it…
STAT+: Nobel Prize, in a rarity, celebrates a fruitful and durable partnership
The most noteworthy aspect of awarding the Nobel Prize in medicine or physiology to two…